From: The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere
Mutation
Assay
Status (%)
PI3KCA (hot spots)
ASPCR
2.7% (4/150)
PTEN loss
IHC
23% (14/61)